Literature DB >> 2904893

The relationship of increased amniotic fluid volume to perinatal outcome.

T R Varma1, S Bateman, R H Patel, G V Chamberlain, U Pillai.   

Abstract

We studied a group of 135 patients with polyhydramnios diagnosed on the basis of ultrasonic findings (greatest vertical diameter of the liquor column greater than or equal to 8.0 cm) between 32 and 36 weeks gestation (study group). We compared the obstetric characteristics and perinatal outcome of the study group with a similar number who constituted our control group. The incidence of women aged 20 years or less was higher in the study group (8.9%) compared with 4.5% in the control group. Of the 135 patients who were diagnosed to have polyhydramnios ultrasonically, the clinical diagnoses prior to referral for ultrasonic scanning, were, suspected large for date fetuses in 34 patients (25.2%), clinically suspected polyhydramnios in 28 (20.7%), gestational diabetes in 21 (15.6%) and insulin dependent diabetes in 6 (4.4%) compared with 13.3%, 5.2%, 3.0% and 0.7%, respectively in the control group (P less than 0.05). Preterm delivery occurred in 11.1% in the study group compared with the incidence of 6.7% in the control group. The incidence of fetal distress, low Apgar Score, macrosomic infants, major fetal anomalies, gross and corrected perinatal mortality rate and admission to special/intensive care nursery was significantly higher in the study group compared with that of the control (P less than 0.01). We found ultrasonic examination is a reliable technique to assess the amount of amniotic fluid volume and it alerts the clinician to possible future problems in pregnancy, labor and neonatal period.

Entities:  

Mesh:

Year:  1988        PMID: 2904893     DOI: 10.1016/0020-7292(88)90108-7

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  1 in total

1.  Maternal smoking and the risk of polyhydramnios.

Authors:  W Myhra; M Davis; B A Mueller; D Hickok
Journal:  Am J Public Health       Date:  1992-02       Impact factor: 9.308

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.